Atlas Trials

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical trial NCT02225275 · TERMINATED

Trial details

NCT number
NCT02225275
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Start date
2016-03-31
Primary completion
2021-05-19
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.